Litigation Details for Vifor Fresenius Medical Care Renal Pharma Ltd. v. Lupin Atlantis Holdings SA (D. Del. 2018)

Vifor Fresenius Medical Care Renal Pharma Ltd. v. Lupin Atlantis Holdings SA (D. Del. 2018)

Docket		Date Filed	2018-03-12
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	None	Referred To
Patents	9,561,251
Link to Docket	External link to docket

Details for Vifor Fresenius Medical Care Renal Pharma Ltd. v. Lupin Atlantis Holdings SA (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-08-13	256	Order - -Memorandum and Order	claims 29, 30, 31 and 51 of U.S. Patent No. 9,561,251 (“the ’251 patent”). In connection with narrowing…this 13th day of August 2020: This is a patent case brought by Plaintiffs Vifor Fresenius Medical…aware of when he submitted a declaration to the Patent Office in 2015. (D.I. 216 at 8-10). Defendants…signed and submitted his sworn declarations” to the Patent Office. (D.I. 225 at 5 (emphasis in original)).… 12 March 2018 1:18-cv-00390-MN Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2022-08-18	325	Opinion - Memorandum Opinion	expiration of United States Patent No. 9,561,251 (JTX-1 (“the ’251 patent”)). Plaintiffs allege that … U.S. Patent No. 6,174,442 (JTX-3) 88. U.S. Patent No. 6,174,442 (“the ’442 patent”) is titled… U.S. Patent No. 4,970,079 (“the ’079 patent”) (JTX-5) 118. The ’079 patent is titled … Blocking Patent 181. Teva asserts that the ’442 patent is a “blocking patent, which disincentivized…the earlier [U.S. Patent No. 4,970,079 patent (“the ’079 Patent”)], which [a POSA would have understood	External link to document